Annual Congress Berlin 2001

Saturday, 22.09.2001
Sunday, 23.09.2001
Monday, 24.09.2001
Tuesday, 25.09.2001
Wednesday, 26.09.2001

Citations should be made in the following way: Authors. Title. Eur Respir J 2004; 18: Suppl. 33, abstract number.

Material from 2001:

3025 Abstracts

Material from 2001: Show

Combination of long-acting B2-agonists and corticosteroids in obstructive airways disease

Oral Presentation
Chairs: E. Bateman (Cape Town, South Africa), K. F. Rabe (Leiden, The Netherlands)

Download all media

GOAL (gaining optimal asthma control): a study to assess asthma control T. J. Clark, J. Bousquet, E. D. Bateman, M. H. James (London, Uxbridge, United Kingdom; Montpellier, France; Cape Town, South Africa)
*The salmeterol/fluticasone propionate combination 50/100 μg b.i.d* is effective as initial maintenance therapy in mild and moderate asthmatics** M. L. Lange, K. W. House, C. A. Scott, T. P. Shah, M. L. M. Akveld (Research Triangle Park, United States Of America; Uxbridge, United Kingdom)
Synergy with salmeterol and fluticasone propionate after administration from a single inhaler (Seretide™) S. D. Pyke, L. Frith, J. Pritchard, M. Johnson, A. Theophilus, T. Shah (Uxbridge, United Kingdom; Research Triangle Park, United States Of America)
Treatment effectiveness and exacerbations during one year with seretide compared to fluticasone propionate and salmeterol in mild-to-moderate asthma B. Lundbäck, E. Rönmark, A. C. Jonsson, A. Lindberg, L. G. Larsson, M. H. James (Umea, Lulea, Sweden; , ; Uxbridge, United Kingdom)
Fluticasone/salmeterol combination (FSC) is safe and provides effective long-term (52 week) control in the management of patients with persistent asthma (PA) P. Keith, A. D'Urzo, N. Stepner, L. Simms, C. Scott, K. House (Hamilton, Toronto, Mississauga, Canada; Research Triangle Park, United States Of America)
*Improvements in FEV1 and symptoms in poorly-reversible COPD patients following 24 weeks of treatment with the salmeterol/fluticasone propionate combination 50/500 BID via* the Diskus™inhaler** M. Littner, J. Yates, T. Fischer, D. Horstman, P. Wire (Sepulveda, United States Of America)
Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use G. Della Cioppa, A. Byrne, D. Till, R. Wood (Horsham, United Kingdom; Basel, Switzerland)
Addition of an extra dose of salmeterol (S) diskus to conventional dose of S diskus in patients with COPD S. Centanni, P. Santus, F. Castagna, S. Granata, M. G. Matera, M. Cazzola (Milan, Naples, Italy)